The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of sunitinib in patients with metastatic renal cell carcinoma on hemodialysis.
J. Casper
Consultant or Advisory Role - Pfizer (U)
Honoraria - Pfizer (B)
Research Funding - Pfizer
D. Goebel
Research Funding - Pfizer
V. Gruenwald
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Wyeth
A. Flörcken
Honoraria - Bayer
Other Remuneration - Bayer
D. Mueller
No relevant relationships to disclose
K. Toussaint
No relevant relationships to disclose
B. Metzner
No relevant relationships to disclose